Immunological Basis for Benralizumab Activity in Chronic Obstructive Pulmonary Disease (COPD)
view all Clinical Trials
Overview
The current literature suggests that the mode of action of benralizumab is to deplete eosinophils through a mechanism of antibody-dependent cell-mediated cytotoxicity. This direct cellular cytotoxicity may not explain all of the benralizumab effects. The investigators propose a set of studies to systematically examine the spectrum of effects of this drug on the immune system.
Contact
For more information about this trial or to inquire about eligibility, email [email protected] or call 215-707-1359.